Details Basic Details Status Ongoing Last Updated Thursday, December 7, 2023 Original Posting Date Friday, May 25, 2018 Health Outcome(s) lymphoma Purpose Drug and Outcome Analysis Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR Yes Result(s) (2) Follow-Up Time for Guselkumab, Risankizumab, and Tildrakizumab Users with Plaque Psoriasis: A Descriptive Analysis Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: An Updated Descriptive Analysis Regulatory Link(s) (1) FDA Approval Package Materials